ALT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Altimmune Inc (ALT) is not a strong buy for a beginner investor with a long-term focus at this time. The stock shows weak financial performance, no significant positive trading signals, and a lack of strong catalysts. While analysts have a positive outlook with high price targets, the stock's technical indicators and options data suggest limited short-term upside. The investor may want to wait for clearer signals or improved financial results before considering this stock.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 36.411, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 4.535, with key resistance at 4.749 and support at 4.321. Overall, technical indicators suggest a weak trend with no strong buy signals.
Analysts from Titan Partners and Barclays have initiated coverage with high price targets of $7 and $20, respectively, citing potential for strong Phase III data and undervaluation in the biotech sector. Upcoming Q4 2025 earnings report on March 5, 2026, could provide more clarity on financial performance.
Weak financial performance in Q3 2025, with net income down 16.77% YoY and EPS down 34.38% YoY. The stock is expected to decline further in the short term based on candlestick analysis, with a 70% chance of a -3.35% drop over the next month. No significant insider or hedge fund activity, and no recent congress trading data.
In Q3 2025, revenue remained flat YoY at $5000, while net income dropped significantly to -$19.01M (-16.77% YoY). EPS also declined to -0.21 (-34.38% YoY). Gross margin remained steady at 100%. Overall, the company is struggling with profitability and growth.
Analysts have a positive outlook on Altimmune, with Titan Partners assigning a Buy rating and a $7 price target, and Barclays giving an Overweight rating with a $20 price target. However, both firms acknowledge the high-risk nature of the stock, with potential upside dependent on successful Phase III data for pemvidutide.
